Crystal structure and anticonvulsant activity of (±)-1,2:4,5-di-O-isopropylidene-3,6-di-O-(2-propylpentanoyl)-myo-inositol

Carbohydrate Research

Volumn 342, Issue 11, 2007, Pages 1456-1461

  Moon, Sung C ^a   Echeverría, Gustavo A ^a,b   Punte, Graciela ^a   Ellena, Javier ^c   Bruno Blanch, Luis E ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anticonvulsant; Diketal; Valproic acid; X ray diffraction

Indexed keywords

ANTICONVULSANT ACTIVITY; ENZYMATIC HYDROLYSIS; MOLECULAR CONFORMATION; VALPROIC ACID (VPA);

CRYSTAL STRUCTURE; HYDROGEN BONDS; ORGANIC COMPOUNDS; SINGLE CRYSTALS; X RAY DIFFRACTION ANALYSIS;

DRUG PRODUCTS;

1,2:4,5 DI O ISOPROPYLIDENE 3,6 DI O (2 PROPYLPENTANOYL) MYO INOSITOL; ANTICONVULSIVE AGENT; CARBONYL DERIVATIVE; HYDROXYL GROUP; OXYGEN; PENTETRAZOLE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; ATOM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG STRUCTURE; HYDROGEN BOND; HYDROLYSIS; MOLECULAR INTERACTION; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEIZURE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTICONVULSANTS; CARBOHYDRATE CONFORMATION; CRYSTALLOGRAPHY, X-RAY; ELECTROSHOCK; INOSITOL; MICE; PENTYLENETETRAZOLE; VALPROIC ACID;

MUS;

EID: 34250615913     PISSN: 00086215     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carres.2007.05.004     Document Type: Article

References (24)

1. Streb H., Irvine R.F., Berridge M.J., and Schulz I. Nature 306 (1983) 67-69
2. Irvine R.F., and Schell M.J. Nat. Rev. Mol. Cell Biol. 2 (2001) 327-338
3. Chung S.-K., Chang Y.-T., and Sohn K.-H. Chem. Commun. (Cambridge) (1996) 163-164
4. Gigg J., Gigg R., Payne S., and Conant R. Carbohydr. Res. 142 (1985) 132-134
5. Löscher W. CNS Drugs 16 (2002) 669-694 and references cited therein
6. Bodor N., Moon S.C., and Bruno-Blanch L. Pharmazie 55 (2000) 184-186
7. Rabinowitz I.N., and Kraut J. Acta Crystallogr. 17 (1964) 159-168
8. Cremer D., and Pople J.A. J. Am. Chem. Soc. 97 (1975) 1354-1358
9. Armand V., Louvel J., Pumain R., Ronco G., and Villa P. Epilepsy Res. 22 (1995) 185-192
10. Redecker C., Altrup U., Hoppe D., Hense T., Kreier A., Rabe A., Dusing R., and Speckmann E. J. Neuropharmacol. 39 (2000) 267-281
11. Enraf-Nonius. CAD-4-PC. Version 1.2. Enraf-Nonius: Delft, The Netherlands; 1993.
12. Harms K., and Wocadlo S. xcad-4. Program for Processing CAD-4 Diffractometer Data (1995), University of Marburg, Marburg, Germany
13. Sheldrick G.M. shelxs-86. Program for Crystal Structure Resolution (1985), Univ. of Göttingen, Göttingen, Germany
14. Sheldrick G.M. shelxl-97. Program for Crystal Structures Analysis (1997), Univ. of Göttingen, Göttingen, Germany
15. Coppens P., Leiserowitz L., and Rabinovich D. Acta Crystallogr. 18 (1965) 1035-1038
16. In: Wilson A.J.C. (Ed). International Tables for Crystallography Vol. C (1995), Kluwer Academic, Dordrecht, The Netherlands
17. Spek A.L. Acta Crystallogr., Sect. A 46 (1990) C34
18. Nardelli M. PARST. J. Appl. Crystallogr. 28 (1995) 659
19. Farrugia L.J. ORTEP3 for Windows. J. Appl. Crystallogr. 30 (1997) 565
20. Farrugia, L. J. WinGX. An Integrate System of Windows Programs for the Solution, Refinement and Analysis of Single Crystal X-ray Diffraction Data. Dept. of Chemistry, University of Glasgow, 1997-2003.
21. Porter M., Cereghino M., Gladding R., Hessie B., Kupferberg D., Scoville M., and White D. Cleveland Clinic. Quart. 51 (1984) 293-305
22. Chen A., Weston J.K., and Bratton A.C. Epilepsia 4 (1963) 66-76
23. Litchfield J.T., and Wilcoxon F. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
24. Swinyard E.A., Woodhead J.H., White H.S., and Franklin M.R. Experimental Selection, Quantification, and Evaluation of Anticonvulsivants. In: Levy R., Dreifuss F., Mattson R., Meldrum B., and Penry J. (Eds). Antiepileptic Drugs. 3rd ed. (1989), Raven Press, New York 85-102